Objective To study the clinical value of oxcarbazepine treatment program in primary trigeminal neuralgia.Methods A total of 60 patients with primary trigeminal neuralgia admitted to the Third People's Hospital of Heze from March 2022 to March 2023 were selected as the research objects.According to the different treatment plans,they were divided into the control group and the study group,with 30 cases in each group.The control group was treated with carbamazepine,and the study group was treated with oxcarbazepine.The treatment effect,pain score,and adverse reactions were compared between the two groups.Results The effective rate of the study group(96.67%)was higher than that of the control group(76.67%),and the difference was statistically significant(χ2=5.192,P<0.05).Before treatment,there was no statistically significant difference in pain scores between the two groups(P>0.05).After 4 weeks and 8 weeks of treatment,the pain scores of the study group were lower than those of the control group,and the differences were statistically significant(both P<0.05).The incidence of adverse reactions in the study group(3.33%)was lower than that in the control group(33.33%),and the difference was statistically significant(P<0.05).Conclu-sion The use of oxcarbazepine in the treatment of primary trigeminal neuralgia can not only quickly relieve the pain of patients,but also improve the effect of disease treatment,and the safety of the drug is worth guaranteeing.
维普
万方数据